Here are the staff publications for March 2024.

Compiled by the Health Sciences Library (RMH, RWH, PMCC & Victorian Mental Health) 3rd April 2024.

1. Bateman NW, Abulez T, Soltis AR, McPherson A, Choi S, Garsed DW, Pandey A, Tian C, Hood BL, Conrads KA, Teng PN, Oliver J, Gist G, Mitchell D, Litzi TJ, Tarney CM, Crothers BA, Mhawech-Fauceglia P, Dalgard CL, Wilkerson MD, Pierobon M, Petricoin EF, Yan C, Meerzaman D, Bodelon C, Wentzensen N, Lee JSH, Huntsman DG, Shah S, Shriver CD, Phippen NT, Darcy KM, Bowtell DDL, Conrads TP, Maxwell GL. Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities. NPJ Precis Oncol 2024;8:68.
2. Baumgartner F, Baer C, Bamopoulos S, Ayoub E, Truger M, Meggendorfer M, Lenk M, Hoermann G, Hutter S, Müller H, Walter W, Müller ML, Nadarajah N, Blombery P, Keller U, Kern W, Haferlach C, Haferlach T. Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022. Blood 2024;143:1139-56.
3. Becker-Cohen M, Revel-Vilk S, Frydman D, Dinur T, Tiomkin M, Istaiti M, Arbel N, Bauer P, Cozma C, Rolfs A, Szer J, Zimran A. Rapid home therapy infusion of velaglucerase alfa in naive patients with Gaucher disease. Intern Med J 2024;54:398-403.
4. Behrens K, Brajanovski N, Xu Z, Viney EM, DiRago L, Hediyeh-Zadeh S, Davis MJ, Pearson RB, Sanij E, Alexander WS, Ng AP. ERG and c-MYC regulate a critical gene network in BCR::ABL1-driven B cell acute lymphoblastic leukemia. Sci Adv 2024;10:eadj8803.
5. Best S, Thursky K, Buzza M, Klaic M, Peters S, Guccione L, Trainer A, Francis J. Aligning organisational priorities and implementation science for cancer research. BMC Health Serv Res 2024;24:338.
6. Braat S, Fielding KL, Han J, Jackson VE, Zaloumis S, Xu JXH, Moir-Meyer G, Blaauwendraad SM, Jaddoe VWV, Gaillard R, Parkin PC, Borkhoff CM, Keown-Stoneman CDG, Birken CS, Maguire JL, Bahlo M, Davidson EM, Pasricha SR. Haemoglobin thresholds to define anaemia from age 6 months to 65 years: estimates from international data sources. Lancet Haematol 2024;11:e253-e64.
7. Casan JML, Seymour JF. Degraders upgraded: the rise of PROTACs in hematological malignancies. Blood 2024;143:1218-30.
8. Cavanagh K, McLean LS, Lim AM, Cardin A, Levy SM, Rischin D. Assessment of perineural spread in advanced cutaneous squamous cell carcinomas treated with immunotherapy. Cancer Imaging 2024;24:37.
9. Chen DC, Sandhu DS, O'Brien JS, Eapen R, Moon D, Goad J, Perera ML, Murphy DG, Lawrentschuk N, Kelly BD. Indocyanine green in minimally and maximally invasive genitourinary cancer surgery. BJU Int 2024;133:400-2.
10. Flood MP, Roberts G, Mitchell C, Ramsay R, Michael M, Heriot AG, Kong JC. Impact of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal adenocarcinoma. Asia Pac J Clin Oncol 2024;20:32-40.
11. Forbes D, Lisy K, Wood C, White V, Evans S, Afshar N, Ristevski E, Sharma A, Changrani K, Jefford M. Factors beyond diagnosis and treatment that are associated with return to work in Australian cancer survivors-A systematic review. Asia Pac J Clin Oncol 2024;20:198-209.
12. Gates P, Dhillon HM, Krishnasamy M, Wilson C, Gough K. Cancer-related cognitive impairment and wellbeing in patients with newly diagnosed aggressive lymphoma compared to population norms and healthy controls: an exploratory study. Support Care Cancer 2024;32:238.
13. Gatt-Rutter T, Forrest L, Sexton A, Isbister J. Consumer attitudes and preferences toward psychiatric genetic counselling and educational resources: A scoping review. Patient Educ Couns 2024;123:108229.
14. Gong JY, Chiang C, Wark JD, Ritchie D, Panek-Hudson Y, Le MV, Limbri L, Fabila N, Fourlanos S, Yates CJ. Bone Density and Trabecular Bone Score Decline Rapidly in the First Year After Bone Marrow Transplantation with a Marked Increase in 10-Year Fracture Risk. Calcif Tissue Int 2024;114:377-85.
15. Griffin M, Kelly RJ, Panse J, de Castro C, Szer J, Horneff R, Tan L, Yeh M, Peffault de Latour R. Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH. Blood Adv 2024;8:1776-86.
16. Gunjur A, Shao Y, Rozday T, Klein O, Mu A, Haak BW, Markman B, Kee D, Carlino MS, Underhill C, Frentzas S, Michael M, Gao B, Palmer J, Cebon J, Behren A, Adams DJ, Lawley TD. A gut microbial signature for combination immune checkpoint blockade across cancer types. Nat Med 2024;30:797-809.
17. Hardcastle N, Vasquez Osorio E, Jackson A, Mayo C, Aarberg AE, Ayadi M, Belosi F, Ceylan C, Davey A, Dupuis P, Handley JC, Hemminger T, Hoffmann L, Kelly C, Michailidou C, Muscat S, Murrell DH, Pérez-Alija J, Palmer C, Placidi L, Popovic M, Rønde HS, Selby A, Skopidou T, Solomou N, Stroom J, Thompson C, West NS, Zaila A, Appelt AL. Multi-centre evaluation of variation in cumulative dose assessment in reirradiation scenarios. Radiother Oncol 2024;194:110184.
18. Hayes AJ, Coker DJ, Been L, Boecxstaens VW, Bonvalot S, De Cian F, de la Cruz-Merino L, Duarte C, Eggermont A, Farricha V, Fiore M, Grünhagen D, Grützmann R, Honoré C, Jakob J, Hocevar M, van Houdt W, Klauzner J, Kettelhack C, Märten A, Martinez-Said H, Matter M, Michot A, Niethard M, Pennacchioli E, Podleska LE, Rabago G, Rastrelli M, Reijers S, Ribeiro M, Schwarzbach M, Snow HA, Spacek M, Stoldt S, Testori A, Zoras O, Olofsson Bagge R. Technical considerations for isolated limb perfusion: A consensus paper. Eur J Surg Oncol 2024;50:108050.
19. Hosseini-Moghaddam SM, Kothari S, Humar A, Albasata H, Yetmar ZA, Razonable RR, Neofytos D, D'Asaro M, Boggian K, Hirzel C, Khanna N, Manuel O, Mueller NJ, Imlay H, Kabbani D, Tyagi V, Smibert OC, Nasra M, Fontana L, Obeid KM, Apostolopoulou A, Zhang SX, Permpalung N, Alhatimi H, Silverman MS, Guo H, Rogers BA, MacKenzie E, Pisano J, Gioia F, Rapi L, Prasad GVR, Banegas M, Alonso CD, Doss K, Rakita RM, Fishman JA. Adjunctive glucocorticoid therapy for Pneumocystis jirovecii pneumonia in solid organ transplant recipients: A multicenter cohort, 2015-2020. Am J Transplant 2024;24:653-68.
20. Hunter D, Anderson N, Oates R, Kok D, Sapkaroski D, Treffry N, Wright C. Piloting a language translation device for Mandarin-speaking patients presenting for radiotherapy treatment-assessing patient and radiation therapist perspectives. Support Care Cancer 2024;32:234.
21. Hyatt A, Gough K, Chung H, Wood W, Aston R, Cockwill J, Galetakis S, Krishnasamy M. Development of consensus quality indicators for cancer supportive care: a Delphi study and pilot testing. BMC Health Serv Res 2024;24:377.
22. Ingley KM, Zatzman M, Fontebasso AM, Lo W, Subasri V, Goldenberg A, Li Y, Davidson S, Kanwar N, Waldman L, Brunga L, Babichev Y, Demicco EG, Gupta A, Szybowska M, Thipphavong S, Malkin D, Villani A, Shlien A, Gladdy RA, Kim RH. Genomic and clinical characterization of a familial GIST kindred intolerant to imatinib. NPJ Genom Med 2024;9:24.
23. Jiménez-Gracia L, Marchese D, Nieto JC, Caratù G, Melón-Ardanaz E, Gudiño V, Roth S, Wise K, Ryan NK, Jensen KB, Hernando-Momblona X, Bernardes JP, Tran F, Sievers LK, Schreiber S, van den Berge M, Kole T, van der Velde PL, Nawijn MC, Rosenstiel P, Batlle E, Butler LM, Parish IA, Plummer J, Gut I, Salas A, Heyn H, Martelotto LG. FixNCut: single-cell genomics through reversible tissue fixation and dissociation. Genome Biol 2024;25:81.
24. Kennedy OJ, Glassee N, Kicinski M, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Giacomo AMD, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Gandini S, Buhrer E, Suciu S, Robert C, Eggermont AMM, Mandala M, Lorigan P, Valpione S. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer 2024;201:113585.
25. Lai-Kwon J, Rutherford C, Jefford M, Gore C, Best S. Using Implementation Science Frameworks to Guide the Use of Electronic Patient-Reported Outcome Symptom Monitoring in Routine Cancer Care. JCO Oncol Pract 2024;20:335-49.
26. Larkins K, Quirke N, Ong HI, Mohamed JE, Heriot A, Warrier S, Mohan H. The deconstructed procedural description in robotic colorectal surgery. J Robot Surg 2024;18:147.
27. Lee C, Dennett AM, Pinson JA, Lewis AK. Caffeine consumed prior to cardiac stress testing may affect diagnostic accuracy of nuclear medicine myocardial imaging of myocardial ischemia: A systematic review and meta-analysis. J Med Imaging Radiat Sci 2024;55:134-45.
28. Lefkovits Y, Lipton L. Botulinum toxin: a new differential diagnosis for a lytic bone lesion. J Med Case Rep 2024;18:179.
29. Lew TE, Bennett R, Lin VS, Whitechurch A, Handunnetti SM, Marlton P, Shen Y, Mulligan SP, Casan J, Blombery P, Tam CS, Roberts AW, Seymour JF, Thompson PA, Anderson MA. Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon. Blood Adv 2024;8:1439-43.
30. Liu G, Mazieres J, Stratmann J, Ou SI, Mok T, Grizzard M, Goto Y, Felip E, Solomon BJ, Bauer TM. A pragmatic guide for management of adverse events associated with lorlatinib. Lung Cancer 2024;191:107535.
31. Liu HY, Hardcastle N, Bailey M, Siva S, Seeley A, Barry T, Booth J, Lao L, Roach M, Buxton S, Thwaites D, Foote M. Guidelines for safe practice of stereotactic body (ablative) radiation therapy: RANZCR 2023 update. J Med Imaging Radiat Oncol 2024;68:217-27.
32. Loeliger J, Francis J, Kiss N, Stewart J, Chandler S, Donohoe K, Hughes V, Swan W, Kaegi K, Elliott A, McIntosh R. Enhancing the provision of cancer nutrition information to support care through experience-based co-design: a mixed-methods study. Support Care Cancer 2024;32:257.
33. Lynch F, Meng Y, Best S, Goranitis I, Savulescu J, Gyngell C, Vears DF. Australian public perspectives on genomic data governance: responsibility, regulation, and logistical considerations. Eur J Hum Genet 2024;32:295-301.
34. Mersiades AJ, Solomon BJ, Thomas DM, Lee CK, Cummins MM, Sebastian L, Ballinger ML, Collignon E, Turnbull OM, Yip S, Morton RL, Brown C, Wheeler PJ, Itchins M, Simes RJ, Pavlakis N. ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue. Future Oncol 2024;20:361-71.
35. Meyer B, Stirzaker C, Ramkomuth S, Harvey K, Chan B, Lee CS, Karim R, Deng N, Avery-Kiejda KA, Scott RJ, Lakhani S, Fox S, Robbins E, Shin JS, Beith J, Gill A, Sioson L, Chan C, Krishnaswamy M, Cooper C, Warrier S, Mak C, Rasko JE, Bailey CG, Swarbrick A, Clark SJ, O'Toole S, Pidsley R. Detailed DNA methylation characterisation of phyllodes tumours identifies a signature of malignancy and distinguishes phyllodes from metaplastic breast carcinoma. J Pathol 2024;262:480-94.
36. Muraro E, Montico B, Lum B, Colizzi F, Giurato G, Salvati A, Guerrieri R, Rizzo A, Comaro E, Canzonieri V, Anichini A, Del Vecchio M, Mortarini R, Milione M, Weisz A, Pizzichetta MA, Simpson F, Dolcetti R, Fratta E, Sigalotti L. Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors. Front Immunol 2024;15:1336566.
37. Nesari Javan F, Askari E, Shafiei S, Roshanravan V, Aghaei A, Ayati N, Zakavi SR. The Prognostic Power of Preablation Stimulated Thyroglobulin in Children With Differentiated Thyroid Cancer. Endocr Pract 2024;30:209-17.
38. Ngo LH, Bert AG, Dredge BK, Williams T, Murphy V, Li W, Hamilton WB, Carey KT, Toubia J, Pillman KA, Liu D, Desogus J, Chao JA, Deans AJ, Goodall GJ, Wickramasinghe VO. Nuclear export of circular RNA. Nature 2024;627:212-20.
39. Nguyen PC, Nguyen T, Wilson C, Tiong IS, Baldwin K, Nguyen V, Came N, Blombery P, Westerman DA. Evaluation of T-cell clonality by anti-TRBC1 antibody-based flow cytometry and correlation with T-cell receptor sequencing. Br J Haematol 2024;204:910-20.
40. Noori J, Yeung T, Pham T, Warrier S, Behrenbruch C, Heriot AG. Revolutionizing colorectal surgery with artificial intelligence: not just a pretty robot. ANZ J Surg 2024;94:295-6.
41. O'Connor D, Valle-Inclan JE, Conde L, Bloye G, Rahman S, Costa JR, Bartram J, Adams S, Wright G, Elrick H, Wall K, Dyer S, Howell C, Jigoulina G, Herrero J, Cortes-Ciriano I, Moorman AV, Mansour MR. Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL. Blood 2024;143:933-7.
42. Orlowski C, Lai J, Vereker M, Antill Y, Richardson G, White M, Gregory P, Kemp S, Morgan J, Ooi C, Senior J, David S. Impact of multidisciplinary team meetings on the management of patients with breast cancer in a large private healthcare facility. Asia Pac J Clin Oncol 2024;20:285-91.
43. Parikh RR, Milgrom SA, Campbell BA. Pushing the CART to the Finish Line: Integrating Radiation Therapy Into Chimeric Antigen Receptor T-Cell Therapy Programs to Improve Outcomes for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys 2024;118:1152-8.
44. Pemberton L, Allen C, Handel E, Weickhardt A, Shapiro J, Tran B, Taylor RA, Risbridger GP, Pook DW. Carboplatin in Metastatic Castrate Resistant Prostate Cancer: A Retrospective Study of Heavily Pretreated Patients (COMPACT). Clin Genitourin Cancer 2024;22:580-5.
45. Piercey O, Wong HL, Leung C, To YH, Heong V, Lee M, Tie J, Steel M, Yeung JM, McCormick J, Gibbs P, Wong R. Adjuvant Chemotherapy for Older Patients With Stage III Colorectal Cancer: A Real-World Analysis of Treatment Recommendations, Treatment Administered and Impact on Cancer Recurrence. Clin Colorectal Cancer 2024;23:95-103 e3.
46. Rajakumaraswamy N, Gandhi M, Wei AH, Sallman DA, Daver NG, Mo S, Iqbal S, Karalliyadda R, Chen M, Wang Y, Vyas P. Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk 2024;24:260-8.e2.
47. Ravandi F, Dohner H, Wei AH, Montesinos P, Pfeilstocker M, Papayannidis C, Lai Y, Wang K, See WL, de Menezes DL, Petrlik E, Prebet T, Roboz GJ. Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001. Br J Haematol 2024;204:877-86.
48. Rischin D, Hughes BGM, Basset-Séguin N, Schadendorf D, Bowyer S, Trabelsi Messai S, Meier F, Eigentler TK, Casado Echarren V, Stein B, Beylot-Barry M, Dalac S, Dréno B, Migden MR, Hauschild A, Schmults CD, Lim AM, Yoo SY, Paccaly AJ, Papachristos A, Nguyen JH, Okoye E, Seebach F, Booth J, Lowy I, Fury MG, Guminski A. High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma. J Immunother Cancer 2024;12:e008325.
49. Ritchie DS. The brain may devise laws for the blood. Blood 2024;143:841-2.
50. Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Ruiz-Borrego M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Afenjar K, Fresco R, Severin I, Ji Y, Ghaznawi F, Li Z, Zarate JP, Chakravartty A, Taran T, Hortobagyi G. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med 2024;390:1080-91.
51. Swanton C, Bernard E, Abbosh C, André F, Auwerx J, Balmain A, Bar-Sagi D, Bernards R, Bullman S, DeGregori J, Elliott C, Erez A, Evan G, Febbraio MA, Hidalgo A, Jamal-Hanjani M, Joyce JA, Kaiser M, Lamia K, Locasale JW, Loi S, Malanchi I, Merad M, Musgrave K, Patel KJ, Quezada S, Wargo JA, Weeraratna A, White E, Winkler F, Wood JN, Vousden KH, Hanahan D. Embracing cancer complexity: Hallmarks of systemic disease. Cell 2024;187:1589-616.
52. Tiong IS, Wall M, Bajel A, Kalro A, Fleming S, Roberts AW, Thiagarajah N, Chua CC, Latimer M, Yeung D, Marlton P, Johnston A, Enjeti A, Fong CY, Cull G, Larsen S, Kennedy G, Schwarer A, Kipp D, Ramanathan S, Verner E, Tiley C, Morris E, Hahn U, Moore J, Taper J, Purtill D, Warburton P, Stevenson W, Murphy N, Tan P, Beligaswatte A, Mutsando H, Hertzberg M, Shortt J, Szabo F, Dunne K, Wei AH. How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials? Blood Cancer J 2024;14:54.
53. Tropea J, Francis JJ, Bennett N, Lim LL, Fetherstonhaugh D, Buising KL, Marshall C, Flynn M, Lim WK, Peters S. Assessing infection prevention and control programs in residential aged care in Australia: A multi-methods cross-sectional study. Geriatr Gerontol Int 2024;24 Suppl 1:358-63.
54. Wallace ND, Alexander M, Xie J, Ball D, Hegi-Johnson F, Plumridge N, Siva S, Shaw M, Harden S, John T, Solomon B, Officer A, MacManus M. The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small-cell lung cancer. Lung Cancer 2024;190:107531.
55. Wang M, Wang LL, Zhong YP, Wang XY, Wang LY, Shi T, Yang LJ, Ji J. Risk perception for fractures and its related factors among family caregivers of underage patients with osteogenesis imperfecta in China: A cross-sectional study. J Pediatr Nurs 2024;77:81-8.
56. Wu Z, Lamao Q, Gu M, Jin X, Liu Y, Tian F, Yu Y, Yuan P, Gao S, Fulford TS, Uldrich AP, Wong CC, Wei W. Unsynchronized butyrophilin molecules dictate cancer cell evasion of Vgamma9Vdelta2 T-cell killing. Cell Mol Immunol 2024;21:362-73.
57. Zeng K, Zhong Y, Chen X, Zhang L. Perceived communication efficacy and unmet needs for chemotherapy-associated symptom management in patients with lung and colorectal cancer: a cross-sectional study. BMC Palliat Care 2024;23:71.
58. Zwimpfer TA, Bilir E, Gasimli K, Cokan A, Bizzarri N, Razumova Z, Kacperczyk-Bartnik J, Nikolova T, Pletnev A, Kahramanoglu I, Shushkevich A, Strojna A, Theofanakis C, Cicakova T, Vetter M, Montavon C, Morgan G, Heinzelmann-Schwarz V. Management of Patients with Hypersensitivity to Platinum Salts and Taxane in Gynecological Cancers: A Cross-Sectional Study by the European Network of Young Gynaecologic Oncologists (ENYGO). Cancers (Basel) 2024;16:1155.